These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 10728691)

  • 1. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.
    Masferrer JL; Leahy KM; Koki AT; Zweifel BS; Settle SL; Woerner BM; Edwards DA; Flickinger AG; Moore RJ; Seibert K
    Cancer Res; 2000 Mar; 60(5):1306-11. PubMed ID: 10728691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
    Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
    Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
    Gupta S; Adhami VM; Subbarayan M; MacLennan GT; Lewin JS; Hafeli UO; Fu P; Mukhtar H
    Cancer Res; 2004 May; 64(9):3334-43. PubMed ID: 15126378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.
    Leahy KM; Ornberg RL; Wang Y; Zweifel BS; Koki AT; Masferrer JL
    Cancer Res; 2002 Feb; 62(3):625-31. PubMed ID: 11830509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of COX-2 inhibition in breast cancer treatment and prevention.
    Arun B; Goss P
    Semin Oncol; 2004 Apr; 31(2 Suppl 7):22-9. PubMed ID: 15179621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis.
    Gately S; Kerbel R
    Prog Exp Tumor Res; 2003; 37():179-92. PubMed ID: 12795055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
    Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
    Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.
    Kismet K; Akay MT; Abbasoglu O; Ercan A
    Cancer Detect Prev; 2004; 28(2):127-42. PubMed ID: 15068837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of colorectal cancer: tumor progression, chemoprevention, and COX-2 inhibition.
    Bresalier RS
    Gastroenterology; 2000 Jul; 119(1):267-8. PubMed ID: 10889181
    [No Abstract]   [Full Text] [Related]  

  • 10. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.
    Harris RE; Alshafie GA; Abou-Issa H; Seibert K
    Cancer Res; 2000 Apr; 60(8):2101-3. PubMed ID: 10786667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy.
    Gately S; Li WW
    Semin Oncol; 2004 Apr; 31(2 Suppl 7):2-11. PubMed ID: 15179620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COX-2 inhibitors. A new class of antiangiogenic agents.
    Masferrer JL; Koki A; Seibert K
    Ann N Y Acad Sci; 1999; 889():84-6. PubMed ID: 10668485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COX-2 inhibitors: cancer trials test new uses for pain drug.
    Michalowski J
    J Natl Cancer Inst; 2002 Feb; 94(4):248-9. PubMed ID: 11854385
    [No Abstract]   [Full Text] [Related]  

  • 14. Arthritis drug approved for polyp prevention blazes trail for other prevention trials.
    Smigel K
    J Natl Cancer Inst; 2000 Feb; 92(4):297-9. PubMed ID: 10675374
    [No Abstract]   [Full Text] [Related]  

  • 15. Cyclooxygenase-2 inhibitors in glioma therapy.
    Giglio P; Levin V
    Am J Ther; 2004; 11(2):141-3. PubMed ID: 14999366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo.
    Sawaoka H; Tsuji S; Tsujii M; Gunawan ES; Sasaki Y; Kawano S; Hori M
    Lab Invest; 1999 Dec; 79(12):1469-77. PubMed ID: 10616198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats.
    Grubbs CJ; Lubet RA; Koki AT; Leahy KM; Masferrer JL; Steele VE; Kelloff GJ; Hill DL; Seibert K
    Cancer Res; 2000 Oct; 60(20):5599-602. PubMed ID: 11059745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
    Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
    Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer.
    Fu SL; Wu YL; Zhang YP; Qiao MM; Chen Y
    World J Gastroenterol; 2004 Jul; 10(13):1971-4. PubMed ID: 15222049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
    Lin E; Morris JS; Ayers GD
    Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):31-7. PubMed ID: 12520638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.